SciELO - Scientific Electronic Library Online

 
vol.39 número4Alucinosis peduncular en esclerosis múltiple, síntoma poco común en la expresión de enfermedad desmielinizanteActualización sobre la comorbilidad migraña-depresión índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Acta Neurológica Colombiana

versión impresa ISSN 0120-8748versión On-line ISSN 2422-4022

Resumen

MONTIEL, Luis Salgado; RIOS-OZUNA, Jhonnys; CABRALES-JUAN, José  y  FRANCO-DAGER, Edwing. Positive and negative myoclonus in a patient with end stage renal disease. Acta Neurol Colomb. [online]. 2023, vol.39, n.4, e8.  Epub 20-Ene-2024. ISSN 0120-8748.  https://doi.org/10.22379/anc.v39i4.860.

Introduction:

Myoclonus are paroxysmal muscle contractions of short duration or abrupt loss of muscle tone, called positive and negative myoclonus respectively. A clinical case of generalized positive and negative myoclonus is presented and the aim is to describe the multiple pathophysiological mechanisms and etiologies that trigger it.

Case presentation:

A 35-year-old man with type 1 diabetes mellitus complicated by diabetic kidney disease on hemodialysis developed catheter-associated bacteremia due to Staphylococcus aureus and presented positive and negative myoclonus. Uremia, infection, and drugs with pro-myoclonic potential were identified as possible triggers; The incidental finding of an ischemic lesion in the caudate nucleus did not explain the semiology found in the patient. The control and removal of all the pro-myoclonic factors mentioned was carried out, along with pharmacological management with levetiracetam, thus achieving control of the symptoms.

Discussion:

Patients with chronic kidney disease are susceptible to the accumulation of guanidine-type toxic products, which have the potential to produce myoclonus. Furthermore, infections, the use of drugs with pro-myoclonic potential and structural lesions such as cortical ischemia are etiologies that should be considered in the differential diagnosis. The greatest impact on symptoms is observed with the control of the triggering factor and if it persists, pharmacological therapy provides good results.

Conclusion:

Myoclonus are relatively common movement disorders in chronic kidney disease. Identification of the trigger is crucial for its management along with the use of drugs with anti-myoclonic activity.

Palabras clave : Chronic kidney disease; Myoclonus; opioid analgesics; Cephalosporins; Gabapentin; Dialysis; Guanidine; Levetiracetam; Uremia.

        · resumen en Español     · texto en Español     · Español ( pdf )